Recent Analyst Stock Rating News
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Get Started for Free
Boobalan Pachaiyappan is an analyst at Roth MKM. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 03/19/2025
| Buy Now | Get Alert | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 03/18/2025 | CRVO | Buy Now | CervoMed | $9.61 | 108.12% | Boobalan Pachaiyappan47% | $15 → $20 | Maintains | Buy | Get Alert |
| 03/11/2025 | CRVO | Buy Now | CervoMed | $9.61 | 56.09% | Boobalan Pachaiyappan47% | $7 → $15 | Maintains | Buy | Get Alert |
| 01/10/2025 | VRNA | Buy Now | Verona Pharma | $63.40 | 7.26% | Boobalan Pachaiyappan47% | → $68 | Initiates | → Buy | Get Alert |
| 01/10/2025 | RVPH | Buy Now | Reviva Pharmaceuticals | $1.08 | 545.46% | Boobalan Pachaiyappan47% | → $7 | Initiates | → Buy | Get Alert |
| 01/10/2025 | CING | Buy Now | Cingulate | $3.68 | 226.09% | Boobalan Pachaiyappan47% | → $12 | Initiates | → Buy | Get Alert |
| 12/24/2024 | GANX | Buy Now | Gain Therapeutics | $2.45 | 185.71% | Boobalan Pachaiyappan47% | $7 → $7 | Maintains | Buy | Get Alert |
| 12/05/2024 | CRVO | Buy Now | CervoMed | $9.61 | 368.26% | Boobalan Pachaiyappan47% | → $45 | Initiates | → Buy | Get Alert |
| 12/05/2024 | TRDA | Buy Now | Entrada Therapeutics | $10.46 | 177.25% | Boobalan Pachaiyappan47% | → $29 | Initiates | → Buy | Get Alert |
| 12/05/2024 | GANX | Buy Now | Gain Therapeutics | $2.45 | 185.71% | Boobalan Pachaiyappan47% | → $7 | Initiates | → Buy | Get Alert |
| 12/05/2024 | LGVN | Buy Now | Longeveron | $1.69 | 492.28% | Boobalan Pachaiyappan47% | → $10 | Initiates | → Buy | Get Alert |
